Novo Nordisk Shares Surge Nearly 10% After FDA Approves New Weight-Loss Pill

We at Market Insight Daily have followed this story closely. On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved a new oral weight‑loss pill from Novo Nordisk. This news sent Novo Nordisk shares sharply higher, nearly 10% up in Frankfurt trading the next day. This is big for the company. It could reshape how millions approach weight loss. It also changes how investors see Novo Nordisk stock.